Review Paper: The role of inflammation in mouse pulmonary neoplasia

Veterinary Pathology

Volumn 46, Issue 3, 2009, Pages 369-390

  Bauer, A K ^a   Rondini, E A ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Genetic susceptibility; Inflammation; Knockout; Mice; Neoplasia; Pharmacologic; Pulmonary; Transgenic

Indexed keywords

MUS;

ANIMAL; INFLAMMATION; LUNG; LUNG TUMOR; MOUSE; PATHOLOGY; REVIEW; RISK FACTOR;

ANIMALS; INFLAMMATION; LUNG; LUNG NEOPLASMS; MICE; RISK FACTORS;

EID: 67649961352     PISSN: 03009858     EISSN: 15442217     Source Type: Journal    
DOI: 10.1354/vp.08-VP-0217-B-REV     Document Type: Review

References (212)

1. Addison CL, Arenberg DA, Morris SB, Xue YY, Burdick MD, Mulligan MS, Iannettoni MD, Strieter RM: The CXC chemokine, monokine induced by interferon-gamma, inhibits non-small cell lung carcinoma tumor growth and metastasis. Hum Gene Ther 11:247-261, 2000
2. Adjei AA: Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 93:1062-1074, 2001
3. Adriaenssens PI, Sivarajah K, Boorman GA, Eling TE, Anderson MW: Effect of aspirin and indo-methacin on the formation of benzo(a)pyrene-induced pulmonary adenomas and DNA adducts in A/HeJ mice. Cancer Res 43:4762-4767, 1983
4. Aggarwal BB: Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 3:745-756, 2003
5. Albina JE, Reichner JS: Role of macrophag-derived nitric oxide in target cell injury. In: Nitric Oxide, Biology, and Pathobiology, ed. Ignarro IJ, pp. 711-724. Academic Press, San Diego, CA, 2000
6. Almawi WY, Melemedjian OK: Molecular mechanisms of glucocorticoid antiproliferative effects: antagonism of transcription factor activity by glucocorticoid receptor. J Leukoc Biol 71:9-15, 2002
7. Alyaqoub FS, Tao L, Kramer PM, Steele VE, Lubet RA, Gunning WT, Pereira MA: Prevention of mouse lung tumors and modulation of DNA methylation by combined treatment with budeso-nide and R115777 (ZarnestraMT). Carcinogenesis 27:2442-2447, 2006
8. Alyaqoub FS, Tao LH, Kramer PM, Steele VE, Lubet RA, Gunning WT, Pereira MA: Prevention of mouse lung tumors and modulation of DNA methylation by combined treatment with budeso-nide and R115777 (ZarnestraMT). Carcinogenesis 28:124-129, 2007
9. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, Andre F, Delaloge S, Tursz T, Kroemer G, Zitvogel L: Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13:1050-1059, 2007
10. Arenberg DA, Kunkel SL, Polverini PJ, Morris SB, Burdick MD, Glass MC, Taub DT, Iannettoni MD, Whyte RI, Strieter RM: Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metasta-ses. J Exp Med 184:981-992, 1996
11. Arnott CH, Scott KA, Moore RJ, Robinson SC, Thompson RG, Balkwill FR: Expression of both TNF-alpha receptor subtypes is essential for optimal skin tumour development. Oncogene 23:1902-1910, 2004
12. Astrakianakis G, Seixas NS, Ray R, Camp JE, Gao DL, Feng Z, Li W, Wernli KJ, Fitzgibbons ED, Thomas DB, Checkoway H: Lung cancer risk among female textile workers exposed to endotox-in. J Natl Cancer Inst 99:357-364, 2007
13. Avis IM, Jett M, Boyle T, Vos MD, Moody T, Treston AM, Martinez A, Mulshine JL: Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J Clin Invest 97:806-813, 1996
14. Bach PB, Jett JR, Pastorino U, Tockman MS, Swensen SJ, Begg CB: Computed tomography screening and lung cancer outcomes. JAMA 297: 953-961, 2007
15. Bailey-Wilson JE, Wiest JS, Anderson MW, Saccomanno G: Genetics of Lung Cancer. In: Biology of Lung Cancer, ed. Kane MA and Bunn PA, pp. 53-98. Marcel Dekker, New York, NY, 1998
16. Balkwill F, Charles KA, Mantovani A: Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7:211-217, 2005
17. Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow? Lancet 357:539-545, 2001
18. Barsky SH, Cameron R, Osann KE, Tomita D, Holmes EC: Rising incidence of bronchioloalveolar lung carcinoma and its unique clinicopathologic features. Cancer 73:1163-1170, 1994
19. Bauer AK, Dixon D, DeGraff LM, Cho HY, Walker CR, Malkinson AM, Kleeberger SR: Tolllike receptor 4 in butylated hydroxytoluene-induced mouse pulmonary inflammation and tumorigenesis. J Natl Cancer Inst 97:1778-1781, 2005
20. Bauer AK, Dwyer-Nield LD, Hankin JA, Murphy RC, Malkinson AM: The lung tumor promoter, butylated hydroxytoluene (BHT), causes chronic inflammation in promotion-sensitive BALB/cByJ mice but not in promotion-resistant CXB4 mice. Toxicology 169:1-15, 2001
21. Bauer AK, Dwyer-Nield LD, Keil K, Koski K, Malkinson AM: Butylated hydroxytoluene (BHT) induction of pulmonary inflammation: a role in tumor promotion. Exp Lung Res 27:197-216, 2001
22. Bauer AK, Dwyer-Nield LD, Malkinson AM: High cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2) contents in mouse lung tumors. Carcino-genesis 21:543-550, 2000
23. Bauer AK, Malkinson AM, Kleeberger SR: Susceptibility to neoplastic and non-neoplastic pulmonary diseases in mice: genetic similarities. Am J Physiol Lung Cell Mol Physiol 287:L685-703, 2004
24. Bauer S, Hangel D, Yu P: Immunobiology of tolllike receptors in allergic disease. Immunobiology 212:521-533, 2007
25. Beato M, Truss M, Chavez S: Control of transcription by steroid hormones. In: Basis for Cancer Management, ed. Castagnetta L, Nenci I, and Bradlow L, pp. 93-123. New York Academy of Sciences, New York, 1996
26. Berger J, Moller DE: The mechanisms of action of PPARs. Annu Rev Med 53:409-435, 2002
27. Bernert H, Sekikawa K, Radcliffe RA, Iraqi F, You M, Malkinson AM: Tnfa and Il-10 deficiencies have contrasting effects on lung tumor susceptibility: gender-dependent modulation of IL-10 haploinsufficiency. Mol Carcinog 38:117-123, 2003
28. Blaine SA, Meyer AM, Hurteau G, Wick M, Hankin JA, Murphy RC, Dannenberg AJ, Geraci MW, Subbaramaiah K, Nemenoff RA: Targeted over-expression of mPGES-1 and elevated PGE2 production is not sufficient for lung tumorigenesis in mice. Carcinogenesis 26:209-217, 2005
29. Boehm U, Klamp T, Groot M, Howard JC: Cellular responses to interferon-gamma. Annu Rev Immunol 15:749-795, 1997
30. Brandacher G, Winkler C, Schroecksnadel K, Margreiter R, Fuchs D: Antitumoral activity of interferon-gamma involved in impaired immune function in cancer patients. Curr Drug Metab 7:599-612, 2006
31. Bren-Mattison Y, Meyer AM, Van Putten V, Li H, Kuhn K, Stearman R, Weiser-Evans M, Winn RA, Heasley LE, Nemenoff RA: Antitumorigenic effects of peroxisome proliferator-activated receptor-gamma in non-small-cell lung cancer cells are mediated by suppression of cyclooxygenase-2 via inhibition of nuclear factor-kappaB. Mol Pharmacol 73:709-717, 2008
32. Campa D, Zienolddiny S, Maggini V, Skaug V, Haugen A, Canzian F: Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis 25:229-235, 2004
33. Campbell WB, Halushka PV: Lipid-derived auto-coids: eicosanoids and platelet-activating factor. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics, ed. Hardman JG, Limbirf LE, Molinoff PB, and Ruddon RW, 9th ed., pp. 601-616. McGraw-Hill, New York, NY, 1996
34. Castonguay A: Inhibition of lung tumorigenesis by NSAIDS: a working hypothesis. Exp Lung Res 24:605-615, 1998
35. Castonguay A, Rioux N, Duperron C, Jalbert G: Inhibition of lung tumorigenesis by NSAIDS: a working hypothesis. Exp Lung Res 24:605-615, 1998
36. Chen D, Jin G, Wang Y, Wang H, Liu H, Liu Y, Fan W, Ma H, Miao R, Hu Z, Sun W, Qian J, Jin L, Wei Q, Shen H, Huang W, Lu D: Genetic variants in peroxisome proliferator-activated receptor-gamma gene are associated with risk of lung cancer in a Chinese population. Carcinogenesis 29:342-350, 2008
37. Cho HY, Jedlicka AE, Reddy SP, Zhang LY, Kensler TW, Kleeberger SR: Linkage analysis of susceptibility to hyperoxia. Nrf2 is a candidate gene. Am J Respir Cell Mol Biol 26:42-51, 2002
38. Cole TJ, Blendy JA, Monaghan AP, Krieglstein K, Schmid W, Aguzzi A, Fantuzzi G, Hummler E, Unsicker K, Schutz G: Targeted disruption of the glucocorticoid receptor gene blocks adrenergic chromaffin cell-development and severely retards lung maturation. Genes Dev 9:1608-1621, 1995
39. Cook DN, Bottomly K: Innate immune control of pulmonary dendritic cell trafficking. Proc Am Thorac Soc 4:234-239, 2007
40. Coussens LM, Werb Z: Inflammation and cancer. Nature 420:860-867, 2002
41. Dajee M, Lazarov M, Zhang JY, Cai T, Green CL, Russell AJ, Marinkovich MP, Tao S, Lin Q, Kubo Y, Khavari PA: NF-kappaB blockade and onco-genic Ras trigger invasive human epidermal neo-plasia. Nature 421:639-643, 2003
42. Dercamp C, Chemin K, Caux C, Trinchieri G, Vicari AP: Distinct and overlapping roles of interleukin-10 and CD25+ regulatory T cells in the inhibition of antitumor CD8 T-cell responses. Cancer Res 65:8479-8486, 2005
43. Doll RJ, Kirschmeier P, Bishop WR: Farnesyl-transferase inhibitors as anticancer agents: critical crossroads. Curr Opin Drug Discov Devel 7: 478-486, 2004
44. Droms KA, Malkinson AM: Mechanisms of glucocorticoid involvement in mouse lung tumori-genesis. Exp Lung Res 17:359-370, 1991
45. Duperron C, Castonguay A: Chemopreventive efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice. Carcinogenesis 18:1001-1006, 1997
46. Dwyer-Nield LD, Srebernak MC, Barrett BS, Ahn J, Cosper P, Meyer AM, Kisley LR, Bauer AK, Thompson DC, Malkinson AM: Cytokines differentially regulate the synthesis of prostanoid and nitric oxide mediators in tumorigenic versus non-tumorigenic mouse lung epithelial cell lines. Carcinogenesis 26:1196-1206, 2005
47. Echchakir H, Vergnon I, Dorothee G, Grunenwald D, Chouaib S, Mami-Chouaib F: Evidence for in situ expansion of diverse antitumor-specific cyto-toxic T lymphocyte clones in a human large cell carcinoma of the lung. Int Immunol 12:537-546, 2000
48. Elder A, Gelein R, Finkelstein JN, Driscoll KE, Harkema J, Oberdorster G: Effects of subchroni-cally inhaled carbon black in three species. I. Retention kinetics, lung inflammation, and histopathology. Toxicol Sci 88:614-629, 2005
49. Engels EA: Inflammation in the development of lung cancer: epidemiological evidence. Expert Rev Anticancer Ther 8:605-615, 2008
50. Engels EA, Wu X, Gu J, Dong Q, Liu J, Spitz MR: Systematic evaluation of genetic variants in the inflammation pathway and risk of lung cancer. Cancer Res 67:6520-6527, 2007
51. Ermert L, Dierkes C, Ermert M: Immunohisto-chemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors. Clin Cancer Res 9:1604-1610, 2003
52. Farrar MA, Schreiber RD: The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol 11:571-611, 1993
53. Faure K, Sawa T, Ajayi T, Fujimoto J, Moriyama K, Shime N, Wiener-Kronish JP: TLR4 signaling is essential for survival in acute lung injury induced by virulent Pseudomonas aeruginosa secreting type III secretory toxins. Respir Res 5:1, 2004 [Abstract]
54. Festing MF, Lin L, Devereux TR, Gao F, Yang A, Anna CH, White CM, Malkinson AM, You M: At least four loci and gender are associated with susceptibility to the chemical induction of lung adenomas in A/J x BALB/c mice. Genomics 53:129-136, 1998
55. Fijneman RJ, Demant P: A gene for susceptibility to small intestinal cancer, ssic1, maps to the distal part of mouse chromosome 4. Cancer Res 55: 3179-3182, 1995
56. Fijneman RJ, de Vries SS, Jansen RC, Demant P: Complex interactions of new quantitative trait loci, Sluc1, Sluc2, Sluc3, and Sluc4, that influence the susceptibility to lung cancer in the mouse. Nat Genet 14:465-467, 1996
57. Fijneman RJ, van der Valk MA, Demant P: Genetics of quantitative and qualitative aspects of lung tumorigenesis in the mouse: multiple interacting Susceptibility to lung cancer (Sluc) genes with large effects. Exp Lung Res 24:419-436, 1998
58. Finetti F, Solito R, Morbidelli L, Giachetti A, Ziche M, Donnini S: Prostaglandin E-2 regulates angiogenesis via activation of fibroblast growth factor receptor-1. J Biol Chem 283:2139-2146, 2008
59. Fosslien E: Review: molecular pathology of cyclo-oxygenase-2 in cancer-induced angiogenesis. Ann Clin Lab Sci 31:325-348, 2001
60. Gately S: The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev 19: 19-27, 2000
61. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, Karin M: IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118: 285-296, 2004
62. Gueders MM, Foidart JM, Noel A, Cataldo DD: Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in the respiratory tract: potential implications in asthma and other lung diseases. Eur J Pharmacol 533:133-144, 2006
63. Gungor N, Godschalk RW, Pachen DM, Van Schooten FJ, Knaapen AM: Activated neutrophils inhibit nucleotide excision repair in human pulmonary epithelial cells: role of myeloperoxidase. Faseb J 21:2359-2367, 2007
64. Gunning WT, Kramer PM, Lubet RA, Steele VE, Pereira MA: Chemoprevention of vinyl carbamate-induced lung tumors in strain a mice. Exp Lung Res 26:757-772, 2000
65. Gunning WT, Kramer PM, Steele VE, Pereira MA: Chemoprevention by lipoxygenase and leukotriene pathway inhibitors of vinyl carbamate-induced lung tumors in mice. Cancer Res 62:4199-4201, 2002
66. Haston CK, Wang M, Dejournett RE, Zhou X, Ni D, Gu X, King TM, Weil MM, Newman RA, Amos CI, Travis EL: Bleomycin hydrolase and a genetic locus within the MHC affect risk for pulmonary fibrosis in mice. Hum Mol Genet 11:1855-1863, 2002
67. Haston CK, Zhou X, Gumbiner-Russo L, Irani R, Dejournett R, Gu X, Weil M, Amos CI, Travis EL: Universal and radiation-specific loci influence murine susceptibility to radiation-induced pulmonary fibrosis. Cancer Res 62:3782-3788, 2002
68. Hayes JD, Pulford DJ: The glutathione S-transfer-ase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemo-protection and drug resistance. Crit Rev Biochem Mol Biol 30:445-600, 1995
69. He TC, Chan TA, Vogelstein B, Kinzler KW: PPAR delta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99:335-345, 1999
70. Herschman HR: Prostaglandin synthase 2. Biochim Biophys Acta 1299:125-140, 1996
71. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, Ogawa M, Mitsudomi T, Sugiura T, Takahashi T: Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Research 58:3761-3764, 1998
72. Higgins SC, Lavelle EC, McCann C, Keogh B, McNeela E, Byrne P, O'Gorman B, Jarnicki A, McGuirk P, Mills KH: Toll-like receptor 4-mediated innate IL-10 activates antigen-specific regulatory T cells and confers resistance to Borde-tella pertussis by inhibiting inflammatory pathology. J Immunol 171:3119-3127, 2003
73. Hofseth LJ, Hussain SP, Wogan GN, Harris CC: Nitric oxide in cancer and chemoprevention. Free Radic Biol Med 34:955-968, 2003
74. Hold GL, Rabkin CS, Chow WH, Smith MG, Gammon MD, Risch HA, Vaughan TL, McColl KE, Lissowska J, Zatonski W, Schoenberg JB, Blot WJ, Mowat NA, Fraumeni JF Jr, El-Omar EM: A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology 132:905-912, 2007
75. Hollingsworth JW, Whitehead GS, Lin KL, Nakano H, Gunn MD, Schwartz DA, Cook DN: TLR4 signaling attenuates ongoing allergic inflammation. J Immunol 176:5856-5862, 2006
76. Honn KV, Meyer J, Neagos G, Henderson T, Westley C, Ratanatharathorn V: Control of tumor growth and metastasis with prostacyclin and thromboxane synthetase inhibitors: evidence for a new antitumor and antimetastatic agent (BAY g 6575). Prog Clin Biol Res 89:295-331, 1982
77. Houghton AM, Grisolano JL, Baumann ML, Kobayashi DK, Hautamaki RD, Nehring LC, Cornelius LA, Shapiro SD: Macrophage elastase (matrix metalloproteinase-12) suppresses growth of lung metastases. Cancer Res 66:6149-6155, 2006
78. Ischiropoulos H, Thom SR: A comparison of the biological reactivity of nitric oxide and peroxyni-trite. In: Nitric Oxide, Biology, and Pathobiology, pp. 83-90. Academic Press, San Diego, CA. 2000
79. Ishibashi Y, Tanaka S, Tajima K, Yoshida T, Kuwano H: Expression of Foxp3 in non-small cell lung cancer patients is significantly higher in tumor tissues than in normal tissues, especially in tumors smaller than 30 mm. Oncol Rep 15:1315-1319, 2006
80. Itoh T, Tanioka M, Matsuda H, Nishimoto H, Yoshioka T, Suzuki R, Uehira M: Experimental metastasis is suppressed in MMP-9-deficient mice. Clin Exp Metastasis 17:177-181, 1999
81. Jalbert G, Castonguay A: Effects of NSAIDS on NNK-induced pulmonary and gastric tumorigene-sis in A/J mice. Cancer Letters 66:21-28, 1992
82. Jantzen HM, Strahle U, Gloss B, Stewart F, Schmid W, Boshart M, Miksicek R, Schutz G: Cooperativity of glucocorticoid response elements located far upstream of the tyrosine aminotrans-ferase gene. Cell 49:29-38, 1987
83. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57:43-66, 2007
84. Ji H, Houghton AM, Mariani TJ, Perera S, Kim CB, Padera R, Tonon G, McNamara K, Marconcini LA, Hezel A, El-Bardeesy N, Bronson RT, Sugarbaker D, Maser RS, Shapiro SD, Wong KK: K-ras activation generates an inflammatory response in lung tumors. Oncogene 25:2105-2112, 2006
85. Jin Y, Xu Y, Xu M, Xue S: Increased risk of cancer among relatives of patients with lung cancer in China. BMC Cancer 5:146, 2005 [Abstract]
86. Johnson SK, Kerr KM, Chapman AD, Kennedy MM, King G, Cockburn JS, Jeffrey RR: Immune cell infiltrates and prognosis in primary carcinoma of the lung. Lung Cancer 27:27-35, 2000
87. Kamiyama M, Pozzi A, Yang L, DeBusk LM, Breyer RM, Lin PC: EP2, a receptor for PGE(2), regulates tumor angiogenesis through direct effects on endothelial cell motility and survival. Oncogene 25:7019-7028, 2006
88. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD: Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 95:7556-7561, 1998
89. Karin M, Cao Y, Greten FR, Li ZW: NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2:301-310, 2002
90. Keith RL, Geraci MW, Nana-Sinkam SP, Breyer RM, Hudish TM, Meyer AM, Malkinson AM, Dwyer-Nield LD: Prostaglandin E2 receptor subtype 2 (EP2) null mice are protected against murine lung tumorigenesis. Anticancer Res 26:2857-2861, 2006
91. Keith RL, Miller YE, Hoshikawa Y, Moore MD, Gesell TL, Gao B, Malkinson AM, Golpon HA, Nemenoff RA, Geraci MW: Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer. Cancer Res 62:734-740, 2002
92. Keith RL, Miller YE, Hudish TM, Girod CE, Sotto-Santiago S, Franklin WA, Nemenoff RA, March TH, Nana-Sinkam SP, Geraci MW: Pulmonary prostacyclin synthase overexpression chemo-prevents tobacco smoke lung carcinogenesis in mice. Cancer Res 64:5897-5904, 2004
93. Kepka-Lenhart D, Mistry SK, Wu G, Morris SM Jr: Arginase I: a limiting factor for nitric oxide and polyamine synthesis by activated macrophages? Am J Physiol Regul Integr Comp Physiol 279:R2237-2242, 2000
94. Khuder SA, Herial NA, Mutgi AB, Federman DJ: Nonsteroidal antiinflammatory drug use and lung cancer: a metaanalysis. Chest 127:748-754, 2005
95. Kim CF, Jackson EL, Woolfenden AE, Lawrence S, Babar I, Vogel S, Crowley D, Bronson RT, Jacks T: Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121:823-835, 2005
96. Kisley LR: Celecoxib reduces pulmonary inflammation but not lung tumorigenesis in mice. Carcinogenesis 23:1653-1660, 2002
97. Kisley LR, Barrett BS, Bauer AK, Dwyer-Nield LD, Barthel B, Meyer AM, Thompson DC, Malkinson AM: Genetic ablation of inducible nitric oxide synthase decreases mouse lung tumorigenesis. Cancer Res 62:6850-6856, 2002
98. Kisley LR, Barrett BS, Dwyer-Nield LD, Bauer AK, Thompson DC, Malkinson AM: Celecoxib reduces pulmonary inflammation but not lung tumorigenesis in mice. Carcinogenesis 23:1653-1660, 2002
99. Kleeberger SR, Levitt RC, Zhang LY, Longphre M, Harkema J, Jedlicka A, Eleff SM, DiSilvestre D, Holroyd KJ: Linkage analysis of susceptibility to ozone-induced lung inflammation in inbred mice. Nat Genet 17:475-478, 1997
100. Kleeberger SR, Reddy S, Zhang LY, Jedlicka AE: Genetic susceptibility to ozone-induced lung hyperpermeability: role of toll-like receptor 4. Am J Respir Cell Mol Biol 22:620-627, 2000
101. Knight B, Yeoh GC, Husk KL, Ly T, Abraham LJ, Yu C, Rhim JA, Fausto N: Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice. J Exp Med 192:1809-1818, 2000
102. Krishna MT, Chauhan AJ, Frew AJ, Holgate ST: Toxicological mechanisms underlying oxidant pollutant-induced airway injury. Rev Environ Health 13:59-71, 1998
103. Laakkonen A, Kyyronen P, Kauppinen T, Pukkala EI: Occupational exposure to eight organic dusts and respiratory cancer among Finns. Occup Environ Med 63:726-733, 2006
104. Lange JH, Mastrangelo G, Thomulka KW: Will sewage workers with endotoxin-related symptoms have the benefit of reduced lung cancer? Occup Environ Med 60:144-145, 2003
105. Lee KM, Shen M, Chapman RS, Yeager M, Welch R, He X, Zheng T, Hosgood HD, Yang D, Berndt SI, Chanock S, Lan Q: Polymorphisms in immunoregulatory genes, smoky coal exposure and lung cancer risk in Xuan Wei, China. Carcinogenesis 28:1437-1441, 2007
106. Leone V, di Palma A, Ricchi P, Acquaviva F, Giannouli M, Di Prisco AM, Iuliano F, Acquaviva AM: PGE(2) inhibits apoptosis in human adenocarcinoma Caco-2 cell line through Ras-PI3K association and cAMP-dependent kinase A activation. Am J Physiol Gastrointest Liver Physiol 293:G673-G681, 2007
107. Lewis CE, Pollard JW: Distinct role of macrophages in different tumor microenvironments. Cancer Res 66:605-612, 2006
108. Lin L, Festing MF, Devereux TR, Crist KA, Christiansen SC, Wang Y, Yang A, Svenson K, Paigen B, Malkinson AM, You M: Additional evidence that the K-ras protooncogene is a candidate for the major mouse pulmonary adenoma susceptibility (Pas-1) gene. Exp Lung Res 24:481-497, 1998
109. Littman AJ, Jackson LA, Vaughan TL: Chlamydia pneumoniae and lung cancer: epidemiologic evidence. Cancer Epidemiol Biomarkers Prev 14:773-778, 2005
110. Liu CY, Wang CH, Chen TC, Lin HC, Yu CT, Kuo HP: Increased level of exhaled nitric oxide and up-regulation of inducible nitric oxide synthase in patients with primary lung cancer. Br J Cancer 78:534-541, 1998
111. Loser K, Apelt J, Voskort M, Mohaupt M, Balkow S, Schwarz T, Grabbe S, Beissert S: IL-10 controls ultraviolet-induced carcinogenesis in mice. J Immunol 179:365-371, 2007
112. Lubet RA, Zhang ZQ, Wiseman RW, You M: Use of p53 transgenic mice in the development of cancer models for multiple purposes. Exp Lung Res 26:581-593, 2000
113. Maeda S, Kamata H, Luo JL, Leffert H, Karin M: IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121:977-990, 2005
114. Malkinson AM: Genetic studies on lung tumor susceptibility and histogenesis in mice. Environ Health Perspect 93:149-159, 1991
115. Malkinson AM: Molecular comparison of human and mouse pulmonary adenocarcinomas. Exp Lung Res 24:541-555, 1998
116. Malkinson AM: Primary lung tumors in mice: an experimentally manipulable model of human ade-nocarcinoma. Cancer Res 52:2670s-2676s, 1992
117. Malkinson AM: Role of inflammation in mouse lung tumorigenesis: a review. Exp Lung Res 31:57-82, 2005
118. Malkinson AM, Radcliffe RA, Bauer AK: Quantitative trait locus mapping of susceptibilities to butylated hydroxytoluene-induced lung tumor promotion and pulmonary inflammation in CXB mice. Carcinogenesis 23:411-417, 2002
119. Manenti G, Gariboldi M, Fiorino A, Zanesi N, Pierotti MA, Dragani TA: Genetic mapping of lung cancer modifier loci specifically affecting tumor initiation and progression. Cancer Res 57:4164-4166, 1997
120. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M: The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25:677-686, 2004
121. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A: Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23:549-555, 2002
122. Marcus AJ, Broekman MJ, Pinsky DJ: COX inhibitors and thromboregulation. N Engl J Med 347:1025-1026, 2002
123. Mastrangelo G, Fedeli U, Fadda E, Milan G, Lange JH: Epidemiologic evidence of cancer risk in textile industry workers: a review and update. Toxicol Ind Health 18:171-181, 2002
124. Mastrangelo G, Grange JM, Fadda E, Fedeli U, Buja A, Lange JH: Lung cancer risk: effect of dairy farming and the consequence of removing that occupational exposure. Am J Epidemiol 161:1037-1046, 2005
125. McCarthy DD, Summers-Deluca L, Vu F, Chiu S, Gao Y, Gommerman JL: The lymphotoxin pathway: beyond lymph node development. Immunol Res 35:41-54, 2006
126. Meuwissen R, Linn SC, Linnoila RI, Zevenhoven J, Mooi WJ, Berns A: Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell 4:181-189, 2003
127. Meyer AM, Dwyer-Nield LD, Hurteau GJ, Keith RL, O'Leary E, You M, Bonventre JV, Nemenoff RA, Malkinson AM: Decreased lung tumorigenesis in mice genetically deficient in cytosolic phospho-lipase A2. Carcinogenesis 25:1517-1524, 2004
128. Mills CD: Macrophage arginine metabolism to ornithine/urea or nitric oxide/citrulline: a life or death issue. Crit Rev Immunol 21:399-425, 2001
129. Miyashita N, Moriwaki K: H-2-controlled genetic susceptibility to pulmonary adenomas induced by urethane and 4-nitroquinoline 1-oxide in A/Wy congenic strains. Jpn J Cancer Res 78:494-498, 1987
130. Montuschi P, Macagno F, Parente P, Valente S, Lauriola L, Ciappi G, Kharitonov SA, Barnes PJ, Ciabattoni G: Effects of cyclo-oxygenase inhibition on exhaled eicosanoids in patients with COPD. Thorax 60:827-833, 2005
131. Moody TW, Leyton J, Martinez A, Hong S, Malkinson A, Mulshine JL: Lipoxygenase inhibitors prevent lung carcinogenesis and inhibit non-small cell lung cancer growth. Exp Lung Res 24:617-628, 1998
132. Moody TW, Leyton J, Zakowicz H, Hida T, Kang Y, Jakowlew S, You L, Ozbun L, Zia H, Young-berg J, Malkinson A: Indomethacin reduces lung adenoma number in A/J mice. Anticancer Res 21:1749-1755, 2001
133. Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N, Holdsworth H, Turner L, Rollins B, Pasparakis M, Kollias G, Balkwill F: Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 5:828-831, 1999
134. Morrison N, Eisman J: Role of the negative glucocorticoid regulatory element in glucocorticoid repression of the human osteocalcin promoter. J Bone Miner Res 8:969-975, 1993
135. Myrdal PB, Karlage K, Kuehl PJ, Angersbach BS, Merrill BA, Wightman D: Effects of novel 5- lipoxygenase inhibitors on the incidence of pulmonary adenomas in the A/J murine model when administered via nose-only inhalation. Carcinogen-esis 28:957-961, 2007
136. Nathan C: Inducible nitric oxide synthase: what difference does it make? J Clin Invest 100: 2417-2423, 1997
137. Newton R: Molecular mechanisms of glucocorti-coid action: what is important? Thorax 55:603-613, 2000
138. Newton R, Seybold J, Kuitert LME, Bergmann M, Barnes PJ: Repression of cyclooxygenase-2 and prostaglandin E-2 release by dexamethasone occurs by transcriptional and post-transcriptional mechanisms involving loss of polyadenylated mRNA. J Biol Chem 273:32312-32321, 1998
139. Nishikawa M, Stapleton PP, Freeman TA, Gaughan JP, Matsuda T, Daly JM: NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model. J Am Coll Surg 199:428-435, 2004
140. Obata M, Nishimori H, Ogawa K, Lee GH: Identification of the Par2 (Pulmonary adenoma resistance) locus on mouse chromosome 18, a major genetic determinant for lung carcinogen resistance in BALB/cByJ mice. Oncogene 13:1599-1604, 1996
141. O'Garra A, Barrat FJ, Castro AG, Vicari A, Hawrylowicz C: Strategies for use of IL-10 or its antagonists in human disease. Immunol Rev 223:114-131, 2008
142. Ohtsuka Y, Brunson KJ, Jedlicka AE, Mitzner W, Clarke RW, Zhang LY, Eleff SM, Kleeberger SR: Genetic linkage analysis of susceptibility to particle exposure in mice. Am J Respir Cell Mol Biol 22:574-581, 2000
143. Oomen LC, van der Valk MA, Hart AA, Demant P: Glucocorticoid hormone effect on transplacental carcinogenesis and lung differentiation: influence of histocompatibility-2 complex. J Natl Cancer Inst 81:512-517, 1989
144. Parimon T: Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175:712-719, 2007
145. Parkin DM, Bray FI, Devesa SS: Cancer burden in the year 2000: the global picture. Eur J Cancer 37 (Suppl 8): S4-S66, 2001
146. Pepin P, Bouchard L, Nicole P, Castonguay A: Effects of sulindac and oltipraz on the tumorigenicity of 4-(methylnitrosamino)1-(3-pyridyl)-1-butanone in A/J mouse lung. Carcinogenesis 13:341-348, 1992
147. Pereira MA, Li YZ, Gunning WT, Kramer PM, Al-Yaqoub F, Lubet RA, Steele VE, Szabo E, Tao LH: Prevention of mouse lung tumors by budesonide and its modulation of biomarkers. Carcino-genesis 23:1185-1192, 2002
148. Peters-Golden M, Henderson WR: Mechanisms of disease: leukotrienes. N Engl J Med 357:1841-1854, 2007
149. Peters LL, Robledo RF, Bult CJ, Churchill GA, Paigen BJ, Svenson KL: The mouse as a model for human biology: a resource guide for complex trait analysis. Nat Rev Genet 8:58-69, 2007
150. Piazza GA, Rahm AK, Finn TS, Fryer BH, Li H, Stoumen AL, Pamukcu R, Ahnen DJ: Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res 57:2452-2459, 1997
151. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y: NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431:461-466, 2004
152. Pine SR, Mechanic LE, Ambs S, Bowman ED, Chanock SJ, Loffredo C, Shields PG, Harris CC: Lung cancer survival and functional polymorphisms in MBL2, an innate-immunity gene. J Natl Cancer Inst 99:1401-1409, 2007
153. Poltorak A, He X, Smirnova I, Liu MY, Huffel CV, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B: Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282:2085-2088, 1998
154. Prows DR, Shertzer HG, Daly MJ, Sidman CL, Leikauf GD: Genetic analysis of ozone-induced acute lung injury in sensitive and resistant strains of mice. Nat Genet 17:471-474, 1997
155. Raimondi S, Paracchini V, Autrup H, Barros-Dios JM, Benhamou S, Boffetta P, Cote ML, Dialyna IA, Dolzan V, Filiberti R, Garte S, Hirvonen A, Husgafvel-Pursiainen K, Imyanitov EN, Kalina I, Kang D, Kiyohara C, Kohno T, Kremers P, Lan Q, London S, Povey AC, Rannug A, Reszka E, Risch A, Romkes M, Schneider J, Seow A, Shields PG, Sobti RC, Sorensen M, Spinola M, Spitz MR, Strange RC, Stucker I, Sugimura H, To-Figueras J, Tokudome S, Yang P, Yuan JM, Warholm M, Taioli E: Meta- and pooled analysis of GSTT1 and lung cancer: a HuGE-GSEC review. Am J Epidemiol 164:1027-1042, 2006
156. Rao R, Redha R, Macias-Perez I, Su Y, Hao CM, Zent R, Breyer MD, Pozzi A: Prostaglandin E2-EP4 receptor promotes endothelial cell migration via ERK activation and angiogenesis in vivo. J Biol Chem 282:16959-16968, 2007
157. Ray A, Prefontaine KE: Physical association and functional antagonism between the P65 subunit of transcription factor Nf-Kappa-B and the glucocor-ticoid receptor. Proc Nat Acad of Sci USA 91:752-756, 1994
158. Redente EF, Orlicky DJ, Bouchard RJ, Malkinson AM: Tumor signaling to the bone marrow changes the phenotype of monocytes and pulmonary macrophages during urethane-induced primary lung tumorigenesis in A/J mice. Am J Pathol 170:693-708, 2007
159. Riha RL, Yang IA, Rabnott GC, Tunnicliffe AM, Fong KM, Zimmerman PV: Cytokine gene polymorphisms in idiopathic pulmonary fibrosis. Intern Med J 34:126-129, 2004
160. Rioux N, Castonguay A: Prevention of NNK-induced lung tumorigenesis in A/J mice by acet-ylsalicylic acid and NS-398. Cancer Res 58:5354-5360, 1998
161. Ristimaki A, Narko K, Hla T: Down-regulation of cytokine-induced cyclo-oxygenase-2 transcript isoforms by dexamethasone: evidence for post-transcriptional regulation. Biochem J 318:325-331, 1996
162. Ritchie KJ, Henderson CJ, Wang XJ, Vassieva O, Carrie D, Farmer PB, Gaskell M, Park K, Wolf CR: Glutathione transferase pi plays a critical role in
163. Rodenhuis S, Slebos RJ: The ras oncogenes in human lung cancer. Am Rev Respir Dis 142: S27-S30, 1990
164. Sakai DD, Helms S, Carlstedtduke J, Gustafsson JA, Rottman FM, Yamamoto KR: Hormone-mediated repression: a negative glucocorticoid response element from the bovine prolactin gene. Genes Dev 2:1144-1154, 1988
165. Sakao S, Tatsumi K, Igari H, Shino Y, Shirasawa H, Kuriyama T: Association of tumor necrosis factor alpha gene promoter polymorphism with the presence of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 163:420-422, 2001
166. Sakurai T, Maeda S, Chang L, Karin M: Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc Natl Acad Sci USA 103:10544-10551, 2006
167. Santillan AA, Camargo CA, Colditz GA: A metaanalysis of asthma and risk of lung cancer (United States). Cancer Causes Control 14:327-334, 2003
168. Schottenfeld D: Etiology and epidemiology of lung cancer. In: Lung Cancer-Principles and Practice, ed. Pass HI, Mitchell JB, Johnson DH, Turrisi AT, and Minna JD, 2nd ed., pp. 367-388. Lippincott Williams & Wilkins, Philadelphia, PA, 2000
169. Schottenfeld D, Beebe-Dimmer J: Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin 56:69-83, 2006
170. Seitz CS, Lin Q, Deng H, Khavari PA: Alterations in NF-kappaB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-kappaB. Proc Natl Acad Sci USA 95:2307-2312, 1998
171. Seow A, Ng DP, Choo S, Eng P, Poh WT, Ming T, Wang YT: Joint effect of asthma/atopy and an IL-6 gene polymorphism on lung cancer risk among lifetime non-smoking Chinese women. Carcinogen-esis 27:1240-1244, 2006
172. Sharma S, Yang SC, Hillinger S, Zhu LX, Huang M, Batra RK, Lin JF, Burdick MD, Strieter RM, Dubinett SM: SLC/CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10. Mol Cancer 2:22, 2003 [Abstract]
173. Shih CM, Lee YL, Chiou HL, Chen W, Chang GC, Chou MC, Lin LY: Association of TNF-alpha polymorphism with susceptibility to and severity of non-small cell lung cancer. Lung Cancer 52:15-20, 2006
174. Shih CM, Lee YL, Chiou HL, Hsu WF, Chen WE, Chou MC, Lin LY: The involvement of genetic polymorphism of IL-10 promoter in non-small cell lung cancer. Lung Cancer 50:291-297, 2005
175. Sinicrope FA, Half E, Morris JS, Lynch PM, Morrow JD, Levin B, Hawk ET, Cohen DS, Ayers GD, Stephens LC: Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenoma-tous polyposis patients. Cancer Epidemiol Bio-markers Prev 13:920-927, 2004
176. Smith WL, DeWitt DL, Garavito RM: Cyclooxy-genases: structural, cellular, and molecular biology. Annu Rev Biochem 69:145-182, 2000
177. Smoak KA, Cidlowski JA: Mechanisms of gluco-corticoid receptor signaling during inflammation. Mech Ageing Dev 125:697-706, 2004
178. Spira A, Beane JE, Shah V, Steiling K, Liu G, Schembri F, Gilman S, Dumas YM, Calner P, Sebastiani P, Sridhar S, Beamis J, Lamb C, Anderson T, Gerry N, Keane J, Lenburg ME, Brody JS: Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer. Nat Med 13:361-366, 2007
179. Stathopoulos GT, Sherrill TP, Cheng DS, Scoggins RM, Han W, Polosukhin VV, Connelly L, Yull FE, Fingleton B, Blackwell TS: Epithelial NF-kappaB activation promotes urethane-induced lung carci-nogenesis. Proc Natl Acad Sci USA 104:18514-18519, 2007
180. Stolfi C, Fina D, Caruso R, Caprioli F, Sarra M, Fantini MC, Rizzo A, Pallone F, Monteleone G: Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid. Biochem Pharmacol 75:668-676, 2008
181. Taioli E, Benhamou S, Bouchardy C, Cascorbi I, Cajas-Salazar N, Dally H, Fong KM, Larsen JE, Le Marchand L, London SJ, Risch A, Spitz MR, Stucker I, Weinshenker B, Wu X, Yang P: Myeloperoxidase G-463A polymorphism and lung cancer: a HuGE genetic susceptibility to environmental carcinogens pooled analysis. Genet Med 9:67-73, 2007
182. Tannenbaum CS, Tubbs R, Armstrong D, Finke JH, Bukowski RM, Hamilton TA: The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J Immunol 161:927-932, 1998
183. Thun MJ, Henley SJ, Burns D, Jemal A, Shanks TG, Calle EE: Lung cancer death rates in lifelong nonsmokers. J Natl Cancer Inst 98:691-699, 2006
184. Tripodis N, Hart AA, Fijneman RJ, Demant P: Complexity of lung cancer modifiers: mapping of thirty genes and twenty-five interactions in half of the mouse genome. J Natl Cancer Inst 93:1484-1491, 2001
185. Tsujii M, Dubois RN: Alterations in cellular adhesion and apoptosis in epithelial-cells overex-pressing prostaglandin-endoperoxide-synthase-2. Cell 83:493-501, 1995
186. Tumanov AV, Christiansen PA, Fu YX: The role of lymphotoxin receptor signaling in diseases. Curr Mol Med 7:567-578, 2007
187. Ulrich CM: Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharma-cogenetics. Nat Rev Cancer 6:130-140, 2006
188. van Hogerlinden M, Rozell BL, Ahrlund-Richter L, Toftgard R: Squamous cell carcinomas and increased apoptosis in skin with inhibited Rel/ nuclear factor-kappaB signaling. Cancer Res 59:3299-3303, 1999
189. Vojtek AB, Der CJ: Increasing complexity of the Ras signaling pathway. J Biol Chem 273:19925-19928, 1998
190. Walker CR, Bauer AK, Cho HY, Kleeberger SR: The role of lymphotoxin-α in ozone induced pulmonary inflammation. Am J Respir Crit Care Med 177:A785, 2008 [Abstract]
191. Wang HY, Wang RF: Regulatory T cells and cancer. Curr Opin Immunol 19:217-223, 2007
192. Wang Y, Zhang Z, Yan Y, Lemon WJ, LaRegina M, Morrison C, Lubet R, You M: A chemically induced model for squamous cell carcinoma of the lung in mice: histopathology and strain susceptibility. Cancer Res 64:1647-1654, 2004
193. Waterston RH, Lindblad-Toh K, Birney E, Rogers J, Abril JF, Agarwal P, Agarwala R, Ainscough R, Alexandersson M, An P, Antonarakis SE, Attwood J, Baertsch R, Bailey J, Barlow K, Beck S, Berry E, Birren B, Bloom T, Bork P, Botcherby M, Bray N, Brent MR, Brown DG, Brown SD, Bult C, Burton J, Butler J, Campbell RD, Carninci P, Cawley S, Chiaromonte F, Chinwalla AT, Church DM, Clamp M, Clee C, Collins FS, Cook LL, Copley RR, Coulson A, Couronne O, Cuff J, Curwen V, Cutts T, Daly M, David R, Davies J, Delehaunty KD, Deri J, Dermitzakis ET, Dewey C, Dickens NJ, Diekhans M, Dodge S, Dubchak I, Dunn DM, Eddy SR, Elnitski L, Emes RD, Eswara P, Eyras E, Felsenfeld A, Fewell GA, Flicek P, Foley K, Frankel WN, Fulton LA, Fulton RS, Furey TS, Gage D, Gibbs RA, Glusman G, Gnerre S, Goldman N, Goodstadt L, Grafham D, Graves TA, Green ED, Gregory S, Guigo R, Guyer M, Hardison RC, Haussler D, Hayashizaki Y, Hillier LW, Hinrichs A, Hlavina W, Holzer T, Hsu F, Hua A, Hubbard T, Hunt A, Jackson I, Jaffe DB, Johnson LS, Jones M, Jones TA, Joy A, Kamal M, Karlsson EK, Karolchik D, Kasprzyk A, Kawai J, Keibler E, Kells C, Kent WJ, Kirby A, Kolbe DL, Korf I, Kucherlapati RS, Kulbokas EJ, Kulp D, Landers T, Leger JP, Leonard S, Letunic I, Levine R, Li J, Li M, Lloyd C, Lucas S, Ma B, Maglott DR, Mardis ER, Matthews L, Mauceli E, Mayer JH, McCarthy M, McCombie WR, McLaren S, McLay K, McPherson JD, Meldrim J, Meredith B, Mesirov JP, Miller W, Miner TL, Mongin E, Montgomery KT, Morgan M, Mott R, Mullikin JC, Muzny DM, Nash WE, Nelson JO, Nhan MN, Nicol R, Ning Z, Nusbaum C, O'Connor MJ, Okazaki Y, Oliver K, Overton-Larty E, Pachter L, Parra G, Pepin KH, Peterson J, Pevzner P, Plumb R, Pohl CS, Poliakov A, Ponce TC, Ponting CP, Potter S, Quail M, Reymond A, Roe BA, Roskin KM, Rubin EM, Rust AG, Santos R, Sapojnikov V, Schultz B, Schultz J, Schwartz MS, Schwartz S, Scott C, Seaman S, Searle S, Sharpe T, Sheridan A, Shownkeen R, Sims S, Singer JB, Slater G, Smit A, Smith DR, Spencer B, Stabenau A, Stange-Tho-mann N, Sugnet C, Suyama M, Tesler G, Thompson J, Torrents D, Trevaskis E, Tromp J, Ucla C, Ureta-Vidal A, Vinson JP, VonNiederhausern AC, Wade CM, Wall M, Weber RJ, Weiss RB, Wendl MC, West AP, Wetterstrand K, Wheeler R, Whelan S, Wierzbowski J, Willey D, Williams S, Wilson RK, WinterE, Worley KC, WymanD,YangS, Yang SP, Zdobnov EM, Zody MC, Lander ES: Initial sequencing and comparative analysis of the mouse genome. Nature 420:520-562, 2002
194. Wattenberg LW, Estensen RD: Chemopreventive effects of myo-inositol and dexamethasone on benzo[a]pyrene and 4-(methylnitrosoamino)-1-(3-pyridyl)-1- butanone-induced pulmonary carcino-genesis in female A/J mice. Cancer Res 56: 5132-5135, 1996
195. Wattenberg LW, Estensen RD: Studies of chemo-preventive effects of budenoside on benzo[a]pyrene-induced neoplasia of the lung of female A/J mice. Carcinogenesis 18:2015-2017, 1997
196. Wattenberg LW, Wiedmann TS, Estensen RD, Zimmerman CL, Galbraith AR, Steele VE, Kelloff GJ: Chemoprevention of pulmonary carcinogenesis by brief exposures to aerosolized budesonide or beclomethasone dipropionate and by the combination of aerosolized budesonide and dietary myo-inositol. Carcinogenesis 21:179-182, 2000
197. Wattenberg LW, Wiedmann TS, Estensen RD, Zimmerman CL, Steele VE, Kelloff GJ: Chemo-prevention of pulmonary carcinogenesis by aerosolized budesonide in female A/J mice. Cancer Res 57:5489-5492, 1997
198. Whitehead GS, Wang T, DeGraff LM, Card JW, Lira SA, Graham GJ, Cook DN: The chemokine receptor D6 has opposing effects on allergic inflammation and airway reactivity. Am J Respir Crit Care Med 175:243-249, 2007
199. Whyte M, Hubbard R, Meliconi R, Whidborne M, Eaton V, Bingle C, Timms J, Duff G, Facchini A, Pacilli A, Fabbri M, Hall I, Britton J, Johnston I, Di Giovine F: Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphisms. Am J Respir Crit Care Med 162:755-758, 2000
200. Wissink S, van Heerde EC, van der Burg B, van der Saag PT: A dual mechanism mediates repression of NF-kappa B activity by glucocorticoids. Mol Endocrinol 12:355-363, 1998
201. Witschi H, Espiritu I, Ly M, Uyeminami D: The chemopreventive effects of orally administered dexamethasone in Strain A/J mice following cessation of smoke exposure. Inhal Toxicol 17:119-122, 2005
202. Witschi H, Espiritu I, Uyeminami D: Chemopre-vention of tobacco smoke-induced lung tumors in A/J strain mice with dietary myo-inositol and dexamethasone. Carcinogenesis 20:1375-1378, 1999
203. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B: Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9:606-612, 2003
204. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimaki A: Expression of cyclooxy-genase-2 in human lung carcinoma. Cancer Res 58:4997-5001, 1998
205. Wood ME, Kelly K, Mullineaux LG, Bunn PA Jr: The inherited nature of lung cancer: a pilot study. Lung Cancer 30:135-144, 2000
206. Yao RS, Wang Y, Lemon WJ, Lubet RA, You M: Budesonide exerts its chemopreventive efficacy during mouse lung tumorigenesis by modulating gene expressions. Oncogene 23:7746-7752, 2004
207. Yoshino I, Yano T, Murata M, Ishida T, Sugima-chi K, Kimura G, Nomoto K: Tumor-reactive T-cells accumulate in lung cancer tissues but fail to respond due to tumor cell-derived factor. Cancer Res 52:775-781, 1992
208. Yusuf N, Nasti TH, Long JA, Naseemuddin M, Lucas AP, Xu H, Elmets CA: Protective role of Toll-like receptor 4 during the initiation stage of cutaneous chemical carcinogenesis. Cancer Res 68:615-622, 2008
209. Zeni E, Mazzetti L, Miotto D, Lo Cascio N, Maestrelli P, Querzoli P, Pedriali M, De Rosa E, Fabbri LM, Mapp CE, Boschetto P: Macrophage expression of interleukin-10 is a prognostic factor in non-small cell lung cancer. Eur Respir J 30:627-632, 2007
210. Zhang X, Shan P, Qureshi S, Homer R, Medzhitov R, Noble PW, Lee PJ: Cutting edge: TLR4 deficiency confers susceptibility to lethal oxidant lung injury. J Immunol 175:4834-4838, 2005
211. Zienolddiny S, Ryberg D, Maggini V, Skaug V, Canzian F, Haugen A: Polymorphisms of the interleukin-1 beta gene are associated with increased risk of non-small cell lung cancer. Int J Cancer 109:353-356, 2004
212. Zou W: Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6:295-307, 2006